FinnCap reissued their corporate rating on shares of Synairgen (LON:SNG) in a report published on Thursday morning.

Separately, N+1 Singer reiterated an under review rating on shares of Synairgen in a research report on Wednesday, September 6th.

Shares of Synairgen (LON:SNG) opened at GBX 12.88 ($0.17) on Thursday. Synairgen has a 12-month low of GBX 6.88 ($0.09) and a 12-month high of GBX 32 ($0.43).

ILLEGAL ACTIVITY WARNING: “Synairgen (SNG) Earns Corporate Rating from FinnCap” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/synairgen-sng-earns-corporate-rating-from-finncap/1769268.html.

Synairgen Company Profile

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in preclinical development for the treatment of idiopathic pulmonary fibrosis (IPF).

Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.